Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 78.78 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 101.11.
  • The stock is close to a major daily resistance at USD 97.79, which should be gotten rid of so as to gain new appreciation potential.
  • With an enterprise value anticipated at 4.59 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBVIE INC.7.25%140 461
JOHNSON & JOHNSON2.78%395 024
ROCHE HOLDING AG10.13%300 195
NOVARTIS2.72%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.83%197 679
NOVO NORDISK AS13.46%149 779
BRISTOL-MYERS SQUIBB COMPAN..2.24%147 733
AMGEN INC.-7.58%131 403
ASTRAZENECA PLC1.09%130 836
ELI LILLY AND COMPANY8.07%128 743
SANOFI4.14%127 112
GLAXOSMITHKLINE-6.79%106 997
BAYER AG1.76%79 066
ALLERGAN PLC4.70%65 850
CHUGAI PHARMACEUTICAL CO., ..0.70%60 073
More Results
Financials (USD)
Sales 2020 35 984 M
EBIT 2020 17 356 M
Net income 2020 10 791 M
Debt 2020 24 609 M
Yield 2020 5,14%
P/E ratio 2020 10,3x
P/E ratio 2021 9,47x
EV / Sales2020 4,51x
EV / Sales2021 4,05x
Capitalization 138 B
Upcoming event on ABBVIE INC.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision -
4 months EPS revision -
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes